Iodide transport and breast cancer.
Breast cancer is the second most common cancer worldwide and the leading cause of cancer death in women, with incidence rates that continue to rise. The heterogeneity of the disease makes breast cancer exceptionally difficult to treat, particularly for those patients with triple-negative disease. To address the therapeutic complexity of these tumours, new strategies for diagnosis and treatment are urgently required. The ability of lactating and malignant breast cells to uptake and transport iodide has led to the hypothesis that radioiodide therapy could be a potentially viable treatment for many breast cancer patients. Understanding how iodide is transported, and the factors regulating the expression and function of the proteins responsible for iodide transport, is critical for translating this hypothesis into reality. This review covers the three known iodide transporters - the sodium iodide symporter, pendrin and the sodium-coupled monocarboxylate transporter - and their role in iodide transport in breast cells, along with efforts to manipulate them to increase the potential for radioiodide therapy as a treatment for breast cancer.
['Poole|Vikki L|VL|', 'McCabe|Christopher J|CJ|']
D000818:Animals D001692:Biological Transport D001940:Breast D001943:Breast Neoplasms D005260:Female D006801:Humans D007454:Iodides D007774:Lactation D026901:Membrane Transport Proteins D008954:Models, Biological D027501:Monocarboxylic Acid Transporters D009363:Neoplasm Proteins D000076988:Sulfate Transporters D027981:Symporters
iodide transport breast cancer radioiodide pendrin sodium iodide symporter (NIS) sodium-coupled monocarboxylate transporter (SMCT)